DA
LEGN icon

Duality Advisers’s Legend Biotech LEGN Stock Holding History

Duality Advisers’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-28,371
Closed -$1.42M – 674
2022
Q4 		$1.42M Buy
+28,371
New +$1.37M 0.16% 231

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Duality Advisers's LEGN Position: Q1 2023 in Review

Duality Advisers sold out of Legend Biotech (LEGN) in Q1 2023, closing a stake of 28,371 shares — an estimated $1.42M sold.

Duality Advisers first reported a position in LEGN in Q4 2022 and held it in 1 quarter. The position peaked at $1.42M in Q4 2022. 160 funds tracked by Wall St. Rank hold LEGN as of Q1 2023.

  • Duality Advisers reported no remaining Legend Biotech position as of Q1 2023 after selling out during the quarter.
  • Duality Advisers sold 28,371 Legend Biotech shares in Q1 2023, an estimated $1.42M.
  • Duality Advisers first reported a position in Legend Biotech in Q4 2022 and held it in 1 quarter.
  • Duality Advisers's Legend Biotech position peaked at $1.42M in Q4 2022.
  • 160 funds tracked by Wall St. Rank held Legend Biotech as of Q1 2023.

Based on Duality Advisers's 13F filing for Q1 2023, filed 27 Jun 2023.